BRUSSELS, January 20, 2016 /PRNewswire/ --
It is with great concern that our federation learned about the death and serious illnesses occurring in an exploratory clinical trial of a new potential medicine. Our thoughts are with the trial participants and their families.
Little is yet known about potential causes. We must await the outcomes of the ongoing investigations by the French Authorities. Once the facts are shared we will be in a position to evaluate what can be learned. Our federation will continue working with other clinical trials stakeholders - regulators, innovators, patients and researchers - to minimise risks in early development of much needed new medicines.
EUFEMED is a federation representing associations and their professional members who are involved in the early stages of the development of new medicines across Europe.
European Federation for Exploratory Medicines Development (EUFEMED)
CONTACT: Dr. Ulrike Lorch MD FRCA FFPM, email@example.com,+44(0)20-8664-5200, EUFEMED: www.eufemed.eu, Representing associations:AGAH www.agah.eu, AHPPI www.ahppi.org.uk, Club Phase I www.clubphase1.com,BAPU www.bapu.be